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1. Introduction 
A significant increase in autoimmune disease morbidity has been observed in recent 
years, including disorders manifesting in childhood, concurrent with decreased age of 
patients at  the time of diagnosis. Autoimmune diseases can involve almost every organ 
system but the endocrine, connective tissue and gastrointestinal systems are the most 
commonly affected 1, 2, 3. 
In terms of epidemiology, autoimmune thyroid diseases (AITD) and diabetes type 1 (T1DM) 
come to the fore among autoimmune diseases related to the endocrine system, whereas 
among those unrelated to the endocrine system celiac disease (CD) is one of the more 
common. These diseases, apart from bronchial asthma, are among the most frequent chronic 
diseases affecting infants and children and often occur together 1, 3 , 4. 
Autoimmune polyendocrinopathy syndrome (APS) or polyglandular autoimmune diseases 
(PGAD) concern primary deficits in two or more endocrine glands and manifest themselves, 
except for Graves’ disease, as organ hypofunction. The main autoimmune endocrinopathies 
are: type 1 diabetes mellitus, autoimmune thyroid diseases, autoimmune adrenal failure 
(Addison disease), hypergonadotropic hypogonadism (premature ovarian failure), 
autoimmune hypoparathyroidism, and pituitary defects (lymphocytic hypophysitis) 5, 6, 7 
Those syndromes are often associated with other non-endocrine autoimmune diseases 5, 6, 7. 
For descriptive purposes three to four different types of APS or PGAD have been described. 
Addison disease is a common element of the first two types i.e. APS-1 Blizzard syndrome, 
APS-2 Schmidt’s syndrome (Carpenter’s syndrome). APS-3, on the other hand, is 
characterised by the presence of autoimmune thyroid disease and diabetes type 1 (3a), 
pernicious anaemia (3b) or vitiligo, alopecia or other organ specific autoimmune disease 
(3c). 
Some authors also distinguish type 4 disease/syndrome, which comprises varied 
combinations of autoimmune diseases with the exception of those mentioned above as types 
1 and 2. A patient with diagnosed T1DM and CD can be included in this group 5, 6, 7.  
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In 1969, Walker-Smith and Grigo8 described a child with T1DM and CD for the first time, 
highlighting the frequent coexistence of these two diseases. What makes CD unique among 
autoimmune diseases is the fact that the external or initiating factor is known, which is not 
the case in T1DM or AITD. 
2. Pathophysiology 
Recent studies have shown that, apart from environmental causes, such as the ingestion of 
gluten in celiac disease, other less understood factors like in T1DM, and recent advances in 
our understanding of genetic predisposition factors, many autoimmune disorders are 
associated with either primary or secondary disturbances in gastrointestinal mucosal 
permeability. 
Gastrointestinal epithelial cells form the largest body surface area interfacing between an 
organism and its external environment. Thanks to tight junctions (TJ), a healthy intestinal 
mucosa serves as a barrier against toxic macromolecules. Under physiological conditions, 
only a few immunologically active antigens can traverse this barrier. Almost 90% of the 
proteins that penetrate the barrier via the epithelium are reduced to non-immunogenic, 
short linear peptides due to the action of lysosomal enzymes. Only a few remain unchanged 
and are transported by M cells or between the enterocytes through TJ. Breaching of the 
epithelial barrier by these antigens often results in the development of immunological 
tolerance rather than triggering the immune response or autoimmunisation 9. An immature 
or damaged mucosa makes the mucous barrier more permeable, which can result in an 
allergic or autoimmune reaction in genetically predisposed individuals 9, 10. Uibo et al. 11 
detected the lowest expression of tight junction protein 1 (TJP1) mRNA in small bowel 
mucosa samples from celiac patients with diabetes mellitus type 1, indicating an increase in 
intestinal permeability. Furthermore, these samples displayed the highest expression of 
forkhead box P3 (FoxP3) mRNA, a marker of regulatory T cells, when compared with 
controls and celiac patients 11. Antigen presenting cells (APC), which present antigens to T 
cells of the intestinal mucosa, are vital to the immunological processes. On their surface, 
they present glycoproteins encoded by major histocompatibility complex (MHC) class I and 
II antigens 12, 13. Almost 50 different conditions, including CD and T1DM, are associated 
with specific MHC class I or II antigen presentation pathways 13. Apart from genetic 
predisposition, the disease or disorder develops when the immune system is exposed to the 
antigen. This process may be enhanced by increased permeability of the mucosa due to 
damaged TJ. According to Fasano et al. 14, 15, 16, 17 an excessive production of zonulin 
stimulated by gluten, increases permeability of TJ. In CD, this process is presumed to be 
mediated by gliadin binding to the chemokine receptor CXCR3 18. 
Gliadin has lately been speculated to be one of the environmental causes of T1DM. Gliadin, 
which contains relatively high levels of glutamine and proline, is a source of polypeptides 
that can penetrate the damaged TJ and presented to T cells by dendritic cells. Activated Th1 
lymphocytes can be stimulated to secret gamma interferon (INF-γ) and tumor-necrosis 
factor-alfa (TNF-α), Th2 lymphocytes to secrete Interleukin-4 (IL-4) and Th17 cells to secrete 
Interleukin-17A (IL-17A). All these cytokines can stimulate a local inflammatory response, 
which further augments the permeability of the mucosa 19, 20, hence resulting in a vicious 
circle that perpetuates damage to the intestinal mucosa.  
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It seems that the development of CD is dependent on the dose, type, timing and method of 
gluten ingestion. Breastfeeding and small amounts of gluten administered with breast milk 
are associated with a reduced risk of developing CD 21, 22. Breastfeeding favours the growth 
of beneficial bacteria, such as Bifidobacterium, and therefore decreases the proliferation of 
others, including those less beneficial, like Bacteroides.  
Diet (and gluten intake) related disorders of the intestinal microflora and permeability of the 
intestinal mucosa appear to play a significant role in the development of T1DM 23. 
According to Visser et al. 24, the influence of gluten on the development of T1DM is as 
follows: a high gluten diet is favourable for Bacteroides, while a gluten-free casein diet 
reduces their number. The predominance of Bacteroides over Bifidobacterium and Lactobacillus, 
which occurs in breastfed babies, stimulates zonulin release 25. In CD zonulin release is 
enhanced by gliadin binding to the chemokine receptor CXCR3 18. An excessive 
concentration of zonulin and its receptor in the enterocyte changes the structure of TJ 
proteins and increases the passage of antigens from the intestinal lumen to the lamina propria 
where antigens are presented to the T cells by the APC. In conjunction with a genetic 
predisposition, this may lead to the trafficking and/or activation of autoaggressive T cells, 
which may provoke autoimmune responses, including destruction of beta cells in T1DM. 
A significant role of gliadin in the etiology and pathogenesis of CD and T1DM has also been 
hypothesized by Barbeau et al 26.  
3. Epidemiology 
Around 4.5% of children and almost 6% of adults with T1DM have concurrent CD 27. This 
correlation between the two diseases seems to become stronger with increasing age and 
duration of diabetes. The epidemiological data vary depending on population characteristics 
as well as on diagnostics criteria. Prevalence of CD among Australian children with newly 
diagnosed T1DM was 1.2% according to Doolan et al.28. This prevalence was 2.7% among 
children with long-standing T1DM and 8.4% among adults.  
In similar populations of children in the USA, the prevalence of CD was 5% percent 
according to Crone et al, and 3.2% according to Sanchez-Albisua et al 29, 30.  
CD coexists with T1DM in only 1.4% of young adults in Wales 31, while the rate is 7.7% in 
children in British Columbia, 2% in adults in the Czech Republic 33, 2.6% in children and 
teenagers in Brazil 34 and 12.3% in adults in Denmark 35. In Iraq it is 11.2% 36, and in Serbia 
5.79% 37. Triolo et al. have found tissue transglutaminase antibodies (anti-tTG) in 11.6% of 
diabetic children, of whom 24.6% had CD 4. In a large study of 28,671 T1DM patients under 
the age of 30 from Germany and Austria, Warncke et al. 38 demonstrated the presence of 
anti-tTG in 10.7% patients, which was associated with the duration of T1DM. In a recent 
study form Greece, Kakleas et al. 39 found an 8.6% prevalence of anti-tTG IgA positivity 
among T1DM children associated with younger age and a shorter duration of diabetes. The 
highest prevalence of 13.8% was documented in Italy by Picarelli et al. 40. This study also 
demonstrated the value of analysing IgA and IgG antibody concentrations simultaneously. 
The prevalence of CD in the patients with T1DM was 6.4% for IgA-EMA-positive, which 
increased to 13.8% when IgG1-EMA was also used for screening.  
The incidence of CD in Polish children with newly diagnosed T1DM was reported to be 
5.7% and 9.4% in those with long-standing T1DM by Mysliwiec et al. 41. There was no 
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significant difference between the positivity for anti-tTG IgA and IgG in those groups. 
Gorska et al. 42 reported 4.1% of newly diagnosed type 1 diabetic children to have positive 
antibodies and our study 43 showed this to be twice as high among girls (5.62%) than among 
boys (2.57%). These data are consistent with other studies i.e. the prevalence of CD is twice 
as high in females as in males. 
Patients with CD also have a greater risk for developing T1DM (around 5%) 44 and diabetes-
associated antibodies are more commonly detected in these individuals. Galii-Tsinopoulou 
et al. 45 detected anti-GAD and IA-2 antibodies in 23% of patients with CD. The same 
authors suggested that a strict gluten-free diet might protect the pancreatic β-cells and thus 
postpone the onset of T1DM. Initiation of a gluten-free diet in T1DM children is associated 
with a significantly reduced risk of autoimmunisation. According to Ludvigsson et al.46, 
early diagnosis of CD (before the age of 2) reduces the risk of developing T1DM before the 
age of 20 when compared to a group diagnosed between the ages of 3 and 20. The 
differences, however were not statistically significant. 
4. Genetic determinants and associations 
Most estimates put the prevalence of CD at close to 1% of the general population 47, and 
recent evidence suggests that serologic prevalence rates have increased fourfold in the past 
50 years 48. The concordance rate for CD in monozygotic twins is 75% and it highlights the 
role of other factors besides genetic predisposition 49. The MHC molecules HLA-DQ2 and 
HLA-DQ8 are risk factors in the disease. Almost 90% of CD patients carry HLA-DQ2 
antigens while most of the rest carry HLA-DQ8 50, 51. HLA-DQ2 molecule is encoded by the 
DQA1*0501 and DQB1*0201 genes 52. 
T1DM is strongly associated with HLA DR3-DQ2 and DR4-DQ8 MHC molecules, and 
associated with DQB1*0302, DQB1*0201, DRB1*0401 and HLA-B alleles 53. Approximately 
90% of CD patients share the HLA DR3/DQ2 configuration 54. The prevalence of tissue 
transglutaminase antibodies has been reported to be as high as 32% in HLA DQ2 
homozygous T1DM patients, compared with 2% in patients without DQ2 or DQ8 55. 
CD and T1DM also share a number of other genetic susceptibility loci. Out of 8 celiac 
susceptibility loci, 6 are associated with T1DM. On the other hand, out of 17 diabetes-
susceptibility loci, 8 are associated with CD 56. At least 8 loci appear to be common for both 
conditions (CCR3, CCR5, SH2B3, RGS1, TAGAP, PTPN2, IL18RAP, CTLA4) 57. It has been 
suggested that the immune or inflammatory responses associated with many autoimmune 
diseases overlap with the function of genes specific for certain diseases, such as IL12A in CD 
and INS in T1DM 57. Two new CD risk regions were recently identified at chromosomes 
6q23.3 (OLIG3-TNFAIP3) and 2p16.1 (REL) 58. Polymorphisms within the TAGAP gene are 
also related to another autoimmune disease: rheumatoid arthritis 59. 
The coexistence of T1DM and CD could be explained by a common genetic factor in the 
HLA region 60, 61 or by molecular mimicry by which gliadin or tissue transglutaminase C 
activates T cells that are cross-reactive with various antigens. During active β-cell 
destruction, transglutaminase C, which is expressed in pancreatic islets, might be presented 
in an immunogenic form. Such inflammatory responses may have the capacity to persist in 
susceptible hosts and lead to chronic organ-specific autoimmune disease 62. Furthermore, it 
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has been suggested that in the development of autoimmunity in T1DM, the failure to 
achieve tolerance to autoantigens is attributable to gut related issues 63.  
5. Diagnosing CD in diabetic patients 
At the time of writing this chapter, duodenal biopsy remains the gold standard for CD 
diagnosis. The diagnostic criteria devised by ESPGHAN in 1989 64 and later modified, 
consist of finding villous atrophy and crypt hyperplasia in a patient who ingests a sufficient 
amount of gluten (the Marsh classification 65) and achieves remission after discontinuing 
gluten from the diet. The diagnosis is further confirmed by positive serology. Highly 
sensitive and specific IgA and IgG antiendomysial antibodies (EmA) and tissue 
transglutaminase antibodies (anti-tTG) are most frequently used. Sometimes, deaminated 
gliadin antibodies (DGP) are also elevated.  
When evaluating anti-EmA and anti-tTG antibodies only of the IgA class (which is often 
preferred due to the lower cost), it is important to note the IgA concentration as well, as the 
frequency of isolated IgA deficiency in celiac patients is almost 2% and 7.7% of patients with 
isolated IgA deficiency suffer from CD 66. 
The above criteria are about to change. With exceptionally high levels of antiendomysial 
antibodies and positive genetic testing (HLA-DQ2, DQ8), CD might be diagnosed without 
histopathologic examination67. The use of three PCR reactions and a single electophoretic 
step for DQA1, DQB1 and DRB1 typing provides distinction of CD associated alleles and 
their homo- or heterozygous status. This analysis reduces reagent costs, personnel and 
instrument time, while enabling improved allelic assignment through HLA-DR-DQ 
haplotype association 68. In case of doubt, when the levels of antibodies are low, duodenal 
biopsy is recommended to confirm the diagnosis. 
6. Evaluation for celiac disease in diabetes mellitus type 1 patients 
T1DM often coexists with CD. However, the latter is often latent, Larsson et al. suggest that 
T1DM patients should be screened annually 69.  
There is no consensus as to whether all diabetic patients should implement a gluten-free 
diet, nor is it clear how often they should be screened for CD.  
The ADA recommends screening diabetic patients for CD and placing all children with a 
confirmed diagnosis of CD on a gluten-free diet (GFD) 70. ISPAD suggests that while it 
seems sensible to put an asymptomatic child on a GFD to avoid the development of disease 
complications, evidence supporting this is still not sufficient. Therefore, they recommend 
that children with confirmed CD and T1DM receive support from a paediatric dietician 71. 
Classical presentation of CD can occur in T1DM patients, but many patients with CD and 
T1DM are either asymptomatic (silent CD) or present with only mild symptoms 72, 73. In a 
recent study from a North American CD clinic, 71.4% of children with diabetes reported no 
gastrointestinal symptoms at the time of a positive screen 74. Some patients are overweight 
or obese at diagnosis; 11.2% of children with CD had a BMI greater than the 90th percentile 
in a recent US study 72. Based on these data, the ISPAD recommendations for the screening 
of all T1DM patients for CD appear to be adequate. Screening for CD should be carried out 
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at the time of diagnosis, annually for the first five years and every second year thereafter. 
More frequent assessment is indicated if the clinical situation suggests the possibility of CD 
or the child has a first-degree relative with CD 71.  
It should be emphasised that both adults and children suffering from CD are at an increased 
risk for sepsis. The risk is highest for pneumococcal sepsis 75. Therefore it is recommended 
to vaccinate these patients against pneumococci.  
Patients with both CD and T1DM have gastrointestinal symptoms more often than those 
who suffer from diabetes only. These include stomach pain, bloating, diarrhea, failure to 
thrive, and decreased appetite. In the study by Naruli et al. 76, this difference was statistically 
significant (p<0.0005). The symptoms subsided after switching onto a gluten-free diet, 
which goes to show that CD was in fact not asymptomatic. Patients who observed the diet 
significantly improved their weight SD score (p=0.008) and BMI SD score (p=0.002) within a 
year.  
In a study by Fröhlich-Reiterer et al. 77, patients with both T1DM and CD (confirmed by a 
biopsy) were diagnosed with diabetes at a younger age and were of a generally lower height 
and weight. Those features were statistically significant (p<0.001) and they continued for 
another five and a half years of observation.  
According to Pitocco et al. 78, patients with both diseases are at higher risk of developing 
atherosclerosis compared to those presenting with diabetes or CD only.  
Other recognised side effects associated with untreated CD in patients with T1DM include 
changes in insulin requirements, frequent hypoglycaemia, failure to thrive, delayed puberty, 
anaemia, osteopenia, osteoporosis and neurologic complications 79, 80, 81, 82.  
The most clinically serious, but rare, complication associated with CD (usually the type 
resistant to treatment) is the development of small intestinal lymphoma83. The incidence of 
this malignancy in patients with both CD and T1DM, however, has not been adequately 
assessed.  
In conclusion, it appears that despite being inconvenient and restrictive, a gluten-free diet 
should be implemented for all patients suffering from T1DM and CD. There is evidence that 
this diet might be effective in protecting the pancreatic β-cells and increasing the levels of 
insulin secretion in newly diagnosed patients 84, 85, 86. A gluten-free diet is beneficial for 
diabetic patients. It improves the indicators of physical development, reduces the risk of 
atherosclerosis and sepsis (especially pneumococcal), and relieves the gastrointestinal 
symptoms associated with untreated CD.  
We strongly suggest that annual screening for CD become part of routine practice in 
patients with T1DM.  
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